©XXXX Daiichi Sankyo, Inc. and AstraZeneca
US-84238, PP-US-8201a-1849;US-93987,PP-US-8201a-2036 XX/XX
For healthcare professionals only
Welcome to the new, updated HER2Know
We have expanded our resource library so you can now explore content on HER2 in tumors beyond breast.
Looking for the original HER2Know breast cancer resources?
Assess HER2 IHC clinical cases and see how your scores compare to your peers.
Put your skills to the test as you examine and classify our Pathology Faculty-curated collection of clinical breast cancer cases. Each question features whole slide images and interpretation summaries, helping you take your practice to the next level.
Which HER2 IHC score would you assign to this slide?
View whole slide imageYour score is aligned!
Your IHC score:
IHC 0
Consensus IHC score:
IHC 0
This is a challenging case where about 10% of tumor cells display a faint/barely perceptible incomplete membranous staining. In such borderline cases, screening the slide multiple times from low (4X) to high magnification (20X-40X) is needed.
As this tumor has a poorly differentiated morphology, repeating the IHC on a different specimen, such as an excision, might be considered. A larger tissue sample from high-grade tumors might show a different IHC result from the one obtained from a tissue biopsy.
Not aligned with the Pathology Faculty score
Your IHC score:
IHC 0
Consensus IHC score:
IHC 0
This is a challenging case where about 10% of tumor cells display a faint/barely perceptible incomplete membranous staining. In such borderline cases, screening the slide multiple times from low (4X) to high magnification (20X-40X) is needed.
As this tumor has a poorly differentiated morphology, repeating the IHC on a different specimen, such as an excision, might be considered. A larger tissue sample from high-grade tumors might show a different IHC result from the one obtained from a tissue biopsy.
Which HER2 IHC score would you assign to this slide?
View whole slide imageYour score is aligned!
Your IHC score:
IHC 0
Consensus IHC score:
IHC 0
Less than 10% of tumor cells display a faint/barely perceptible and mainly incomplete membranous staining. This case could be challenging since the specifically stained tumor cells are scattered while multiple tumor cells only present a non-specific basal staining.
View whole slide imageNot aligned with the Pathology Faculty score
Your IHC score:
IHC 0
Consensus IHC score:
IHC 0
Less than 10% of tumor cells display a faint/barely perceptible and mainly incomplete membranous staining. This case could be challenging since the specifically stained tumor cells are scattered, while multiple tumor cells only present a non-specific basal staining.
View whole slide image
Which HER2 IHC score would you assign to this slide?
View whole slide imageYour score is aligned!
Your IHC score:
IHC 1+
Consensus IHC score:
IHC 1+
This is a challenging case with between 10% and 15% of tumor cells displaying a faint/barely perceptible and incomplete membranous staining.
View whole slide imageNot aligned with the Pathology Faculty score
Your IHC score:
IHC 1+
Consensus IHC score:
IHC 1+
This is a challenging case with between 10% and 15% of tumor cells displaying a faint/barely perceptible and incomplete membranous staining.
View whole slide image
Which HER2 IHC score would you assign to this slide?
View whole slide imageYour score is aligned!
Your IHC score:
IHC 0
Consensus IHC score:
IHC 0
This is an interesting case where several tumor cells exhibit a faint and rarely moderate incomplete membranous staining. However, when carefully examined, the percentage of these stained tumor cells is less than 10%.
The strong staining intensity might create a false impression of a higher number of stained tumor cells.
Not aligned with the Pathology Faculty score
Your IHC score:
IHC 0
Consensus IHC score:
IHC 0
This is an interesting case where several tumor cells exhibit a faint and rarely moderate incomplete membranous staining. However, when carefully examined, the percentage of these stained tumor cells is less than 10%.
The strong staining intensity might create a false impression of a higher number of stained tumor cells.
Which HER2 IHC score would you assign to this slide?
View whole slide imageYour score is aligned!
Your IHC score:
IHC 2+
Consensus IHC score:
IHC 2+
This is an interesting case where more than 10% of tumor cells display a moderate to strong incomplete basolateral or lateral membranous staining. The faint staining might mislead some to score this case 1+.
View whole slide imageNot aligned with the Pathology Faculty score
Your IHC score:
IHC 2+
Consensus IHC score:
IHC 2+
This is an interesting case where more than 10% of tumor cells display a moderate to strong incomplete basolateral or lateral membranous staining. The faint staining might mislead some to score this case 1+.
View whole slide image
Which HER2 IHC score would you assign to this slide?
View whole slide imageYour score is aligned!
Your IHC score:
IHC 1+
Consensus IHC score:
IHC 1+
This an interesting case with several tumor cells displaying a faint/barely perceptible and incomplete membranous staining while some are expressing a strong basolateral or lateral staining. The high intensity staining in less than 10% of tumor cells keeps this case at a lower score.
As this tumor has a poorly differentiated morphology and micropapillary features, repeating the IHC on a different specimen, such as an excision, might be considered. A larger tissue sample from high-grade tumors might show a different IHC result from the one obtained from a tissue biopsy.
Not aligned with the Pathology Faculty score
Your IHC score:
IHC 1+
Consensus IHC score:
IHC 1+
This an interesting case with several tumor cells displaying a faint/barely perceptible and incomplete membranous staining while some are expressing a strong basolateral or lateral staining. The high intensity staining in less than 10% of tumor cells keeps this case at a lower score.
As this tumor has a poorly differentiated morphology and micropapillary features, repeating the IHC on a different specimen, such as an excision, might be considered. A larger tissue sample from high-grade tumors might show a different IHC result from the one obtained from a tissue biopsy.
Which HER2 IHC score would you assign to this slide?
View whole slide imageYour score is aligned!
Your IHC score:
IHC 2+
Consensus IHC score:
IHC 2+
This is a challenging case where about 10% of tumor cells display faint/barely perceptible incomplete membranous staining. In such borderline cases, screening the slide multiple times from low (4X) to high (20X-40X) magnification is needed.
As this tumor has a poorly differentiated morphology, repeating the IHC on a different specimen, such as an excision, might be considered. A larger tissue sample from high-grade tumors might show a different IHC result from the one obtained on a tissue biopsy.
Not aligned with the Pathology Faculty score
Your IHC score:
IHC 1+
Consensus IHC score:
IHC 2+
Less than 10% of tumor cells display a faint/barely perceptible and mainly incomplete membranous staining. This case could be challenging since the specifically stained tumor cells are scattered, while multiple tumor cells only present non-specific basal staining.
View whole slide imageHow does your HER2 IHC scoring compare to your fellow pathologists? Examine these whole slide images and select your score.
Slide 1 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 2 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 3 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 4 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 5 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 6 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 7 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 8 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 9 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 10 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 11 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 12 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 13 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 14 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 15 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 16 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 17 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 18 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 19 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 20 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
Slide 21 OF 21
Which HER2 IHC score would you assign to this case?
Service down. Please try again some time
How of your peers scored this slide
ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
Bureau 58, Building B, Floor 2, Plot No. 58, 4th Sector,
Fifth settlement, New Cairo, Egypt For Drug safety and
adverse event safety please report to: patient.safetyegypt@astrazeneca.com
For Medical information please contact: medinfo-egypt@astrazeneca.com
This site is intended for healthcare professionals only.

©XXXX Daiichi Sankyo, Inc. and AstraZeneca
US-84238, PP-US-8201a-1849;US-93987,PP-US-8201a-2036 XX/XX
Request an AstraZeneca Medical Affairs Representative Follow-Up